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Abstract A highly-parallel yeast functional assay, capa-
ble of screening approximately 100–1,000 mutants in
parallel and designed to screen the activity of transcription
activator proteins, was utilized to functionally characterize
tetramerization domain mutants of the human p53 tran-
scription factor and tumor suppressor protein. A library
containing each of the 19 possible single amino acid
substitutions (57 mutants) at three positions in the tetra-
merization domain of the human p53 protein, was
functionally screened in Saccharomyces cerevisiae. Amino
acids Leu330 and Ile332, whose side chains form a portion
of a hydrophobic pocket that stabilizes the active p53 tet-
ramer, were found to tolerate most hydrophobic amino acid
substitutions while hydrophilic substitutions resulted in the
inactivation of the protein. Amino acid Gln331 tolerated
essentially all mutations. Importantly, highly parallel
mutagenesis and cloning techniques were utilized which, in
conjunction with recently reported highly parallel DNA
sequencing methods, would be capable of increasing
throughput an additional 2–3 orders of magnitude.
Keywords Polonies  p53  Genomics 
High-throughput DNA sequencing
Introduction
The ability to use genotype data to understand complex
phenotypes, for example the ability to predict the suscepti-
bility to infectious disease or the likelihood of developing
cancer based upon one’s genome sequence, was one of the
early dreams of the Human Genome Project. The publication
of the human genome sequence (Lander et al. 2001; Venter
et al. 2001) and ongoing research devoted to describing
genetic variation within the human population (Masood
1999) are initial steps in this effort. One of the next major
steps in the Human Genome Project is to understand the
physiological effect of genetic diversity in the human pop-
ulation. Specifically, it is critical to identify and characterize
the subset of SNPs and other mutations which impact bio-
chemical function. In order to achieve this goal several
additional questions must be addressed. How do we identify
functionally important mutations? How do we identify
functionally important residues within a protein? How do we
analyze the relation between single point mutations and the
complex integrated functions in a cellular system? Herein,
we seek to develop a framework for addressing these ques-
tions in a high-throughput fashion. Specifically, we
developed a highly parallel functional assay based upon the
ability of the human p53 (p53) protein to initiate
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transcription of target proteins under the control of a p53
response element mediated promoter in Saccharomyces ce-
revisiae (Scharer and Iggo 1992). We then used this
functional assay to screen the activity of 57 single codon
mutants (all possible single amino acid substitutions) at
positions Leu330, Gln331 and Ile332 of the human p53 gene.
Our assay was inspired by the FASAY screen initially
reported by Flaman et al. (1995) and its variations (e.g. (Jia
et al. 1997)) and, in fact, utilized a reporter strain devel-
oped for this application (Tomso et al. 2005). Unlike these
assays, which utilize separate colony growth on solid agar
to identify and isolate functional and non-functional p53
expressing strains and standard DNA sequencing to iden-
tify a specific inactivating mutation, we utilized mixed
mutant growth competitions, polymerase colony (polony)
(Mitra and Church 1999) and primer extension sequencing
technology (Mitra et al. 2003) similar to methods we have
reported previously (Merritt et al. 2003; Merritt et al.
(2005). The primary advantage of our methodology is that
mutant enrichment (via mixed strain growth competition)
and identification of the associated mutation(s) (polony
based) are highly parallel. Our assay has the ability to
screen the function of approximately 100–1,000 strains in
parallel. Further, by applying recently reported ultrahigh
throughput DNA sequencing (Margulies et al. 2005;
Shendure et al. 2005) and making minor modifications,
throughput could be increased several orders of magnitude.
As a target for mutation analysis, the p53 gene is of
great interest (Hernandez-Boussard et al. 1999) due to the
high prevalence of mutations in the gene in almost every
type of human cancer. p53 is a tumor suppressor gene that
binds DNA sequences (Kern et al. 1991) and activates the
transcription of various genes including several that induce
cell-cycle arrest and apoptosis (Chappuis et al. 1999). The
p53 monomer contains three primary domains associated
with this function—an N-terminal transactivation domain,
a central DNA binding domain and a tetramerization
domain located near the C-terminus (Ko and Prives 1996).
The majority of identified mutations associated with cancer
(87%) are localized to the DNA binding domain (Levine
et al. 1995). However, mutations which inactivate the
protein have also been identified in the transactivation and
tetramerization domains (Chene and Bechter 1999). The
amino acid positions screened in this work were localized
in a portion of the tetramerization domain encoding a b-
sheet substructure believed to stabilize the assembled
functional p53 tetramer.
Briefly, a strain library was constructed in which p53
mutants were expressed in a p53 reporter strain of Sac-
charomyces cerevisiae. This strain was designed such that
functional p53 expression activated expression of the
ADE2 gene which was essential for growth of the strain in
adenine deficient medium. Library growth enriched strains
expressing p53 mutants with higher activities in the culture
and depleted strains expressing less active p53 mutants
from the culture. Similar growth competition methodology
has been used previously, primarily to determine the
function of native genes via parallel analysis of whole-gene
deletion libraries (Merritt and Edwards 2004). Using this
method we identified both tolerated and non-tolerated
mutations in the three amino acid positions tested. The
identities of tolerated and non-tolerated amino acid sub-
stitutions were interpreted in conjunction with reported
structural and epidemiological data.
Materials and methods
Strain and media
Yeast growth experiments were conducted in the AR-
HGEF7 strain#2152 (Tomso et al. 2005). Briefly, the strain
has been modified to express the ADE2 gene under the
control of a p53 response element mediated promoter. As a
result, the strain can be utilized for standard colony color
screening (Flaman et al. 1995) or selective growth in YPD
for active p53 expression in media low or deficient in
adenine, respectively.
Media used in this work were the following. YPD
(Sherman 1991): 10 g/l yeast extract (Fisher Scientific),
20 g/l peptone (Fisher Scientific), 20 g/l dextrose (Fisher
Scientific). SD: 6.7 g/l Yeast Nitrogen Base Without
Amino Acids (Difco), 20 g/l dextrose. SD was supple-
mented with 0.68 g/l Complete Supplement Mixture—
Adenine-Leucine (Qbiogene) and, prior to introduction of
the plasmid, 30 mg/l leucine (Sigma Aldrich) and either
30, 5 or 0 mg/l adenine (Sigma Aldrich) for general
growth, color screening or selective growth, respectively.
LB: 10 g/l Tryptone (Difco), 5 g/l yeast extract, 10 g/l
NaCl. LB medium was supplemented with 50 mg/l ampi-
cillin. Solid agar media were made using 15 g/l agar
(Fisher Scientific) in the above media.
Nucleic acid manipulation and plasmid construction
Tagged human p53 expression vectors expressing all pos-
sible single amino acid substitutions at amino acid
positions 330, 331, 332 (57 total) were constructed in a
three step process outlined in Fig. 1 using the
p415CYC1hG6PDTag plasmid previously described
(Merritt et al. 2005).
Final tagged mutant p53 expression vectors were
assembled as follows. Both mutant constructs and the set of
plasmids bearing the 200 bp tags were dual digested with
HindIII and SpeI (Invitrogen) and gel purified. Purified
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plasmid and individual mutant digests were mixed in
equimolar quantities (specific tags were matched with each
mutant p53) and ligated using the Quick Ligation Kit (New
England Biolabs). Ligation reactions were transformed into
competent cells, plasmid DNA from each ligation was
isolated and the presence of the gene and tag were con-
firmed by triple digest with Spe I, Hind III and Sal I. The
p53 coding region of each final construct was sequenced to
confirm the identity of the mutation it carried.
Polony slides
Plasmid DNA from the growth competition experiments
was used to quantify the relative concentrations of each
mutant in culture as a function of time. Initially, plasmid
DNA was isolated from culture samples using the Yeast
RPM Plasmid Kit (Qbiogene). This plasmid DNA was then
used as the template in the polony reactions described
below as described in the literature (Merritt et al. 2003;
Merritt et al. 2005). Single Base Extension (SBE)
Sequencing of the sequence tags (STs) (Fig. 2A) was used
to quantify polonies arising from each mutant strain in the
mixed culture as described in the literature (Merritt et al.
2003; Merritt et al. 2005).
Gene expression analysis
Gene expression analysis of individual strains was con-
ducted essentially to verify the expression level of the
p53 gene as described (Merritt et al. 2003; Merritt et al.
2005; Mikkilineni et al. 2004). The ratio of ADE2:p53
was calculated and the % WT activity for each mutant
tested was calculated using a calibration curve
(R2 = 0.93) prepared from the ADE2/p53 ratios of
mutants with previously reported activity (Leu330Ala,
Leu330His, Gln331Ala and Ile332Ala). Western blots
were also performed to verify the protein expression
level. The blot was initially contacted with anti-p53
(Bethyl Laboratories) at a dilution of 1/2000 and then
with anti-Rabbit peroxidase linked secondary antibody
(Amersham) at a dilution of 1/4000. Protein concentra-
tions of each sample were normalized to the value of the
Leu330Tyr mutant.
Red/White color screen for functional p53 expression
A red/white color screen for functional p53 expression
similar to that previously described (Inga et al. 2002)
was conducted on all p53 mutants. Three clones of each
Fig. 1 Construction of tagged mutant p53 expression plasmids.
Plasmids were constructed in a three step process. (A) 200 bp tags
containing six variable positions were synthesized using overlapping
oligonucleotide PCR; tags were cloned into the expression plasmid
using homologous recombination mediated gap repair. (B) Mutant
p53 genes were constructed using mutagenic crossover PCR; both
degenerate (–NNN–) and mutant specific primers were used. (C)
Final plasmid assembly was done by ligating SpeI/HindIII digested
tagged vector and mutant p53 genes from (A) and (B)
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strain transformed with a different mutant p53 bearing
plasmid were plated on media supplemented with a low
concentration (5 mg/l) of adenine and grown at 30C for
four days. Strains were then scored on a scale of 1
(whitest) to 5 (reddest) by three independent evaluators.
The average and standard deviation of the three scores
was reported.
Growth competition for functional p53 expression
Mutant p53 bearing plasmids were pooled in equimolar
quantities and this pool was used to transform the AR-
HGEF7 strain. Approximately 1.5 lg of pooled plasmid
was used in each of four transformations. To ensure library
diversity, the four transformations were then pooled and
this pool was used to inoculate medium for the growth
competition. The competition pool was initially grown in
leucine deficient medium supplemented with 30 mg/l
adenine (selective for presence of p53 expression plasmid
but non-selective for functional p53 expression) for
approximately 10 culture generations. The library was then
transferred to adenine deficient medium and grown to mid-
log phase (OD600 1.0–3.5). Cells from 10 ml of culture
were harvested and stored at –80C for analysis. This cycle
was repeated two additional times so that the competition
lasted 15–20 generations.
Results
Growth competition based p53 functional assay
A library of mutant human p53 expression plasmids was
screened for functionality using a S. cerevisiae growth
competition method. The concentrations of each mutant
bearing strain in culture was measured at several time
points using polonies and single base extensions to identify
the unique tag associated with each mutant p53 gene. The
specific growth rate of each mutant (greater than 0.5% of
the population) was determined using a least-squares curve




Specifically, curve fits to the SBE data were performed







where Xe is an n (number of mutants) · m (number of time
points) matrix containing the experimentally measured
percent concentrations of each mutant at each sampling, l
is a n · 1 matrix containing the specific growth rate of each
strain in the competition and t is a 1 · m matrix containing
the times at which samples were taken and mutant
concentrations measured. All elements of l were allowed
to vary in order to minimize the sum of the square of the
error (R(Error)2) between the calculated and measured
matrix according to the equation:
Fig. 2 (A) Polony method used to quantify mutants during p53
growth competition. Plasmid DNA was initially isolated from the
culture and used as template in a polony PCR. Common primers
amplified all STs, each associated with a different p53 mutant and
resulting in an individual polony. Polonies were identified by
conducting six sequential single-base extensions using fluorescent-
ly-labeled nucleotides. The position of each polony was manually
logged after sybr green staining using Metamorph software (Universal
Imaging). Data from each extension was assembled into the final code
sequence using a simple routine developed in our laboratory. In the
representative frames above, two polonies are traced through all six
extensions. Upper: tag sequence ‘‘AACAAA’’ corresponds to
Gln331Gly. Lower: tag sequence ‘‘TCCCAA’’ corresponds to
Gln331Met. (B) Expression plasmids were constructed using the
p415CYC1 vector which carries the constitutive CYC1 promoter










Results of the growth competition are summarized in
Table 1. Although approximately equal amounts of each
mutant plasmid were initially supplied to the growth
competition, two distinct populations had arisen from this
culture at the first sample point after selection was initiated.
The first population consisted of mutants capable of growth
in the absence of adenine (i.e. expressing functional p53).
The 30 mutants in this population had a narrow range of
growth rates (average: 0.198 h–1, standard deviation:
0.009 h–1). The second population, presumably strains
expressing non-functional p53, consisted of mutants not
present in the competition culture at significant
concentrations at the first sampling point after selection
was initiated or at subsequent time points. It was therefore
not possible to calculate growth rates for this population.
Table 1 Properties of the p53 tetramerization domain mutants
Mutant WT AA Mutant AA Polony l (h–1) Red/White %WT activity p53 Western blot
Leu330Ala Hydrophobic uncharged – 3.7 ± 0.6 5.6 ± 4.2 –
Leu330Arg Hydrophilic basic – 4.3 ± 0.6 – –
Leu330Asn Hydrophilic uncharged – 4.3 ± 0.6 7.2 ± 14.4 –
Leu330Asp Hydrophilic acidic – 5.0 ± 0 47.6 ± 8.0 121.7% ± 8.3%
Leu330Cys Uncharged hydrophobic 0.174 1.7 ± 0.6 – –
Leu330Gln Hydrophilic uncharged – 3.0 ± 0 – –
Leu330Glu Hydrophilic acidic – 5.0 ± 0 54.4 ± 22.3 –
Leu330Gly Uncharged – 5.0 ± 0 5.5 ± 5.4 –
Leu330His Hydrophilic basic – 4.3 ± 0.6 7.6 ± 10.0 –
Leu330Ile Hydrophobic uncharged 0.196 1.3 ± 0.6 250.5 ± 7.4 –
Leu330Lys Hydrophilic basic – 5.0 ± 0 29.9 ± 16.2 –
Leu330Met Hydrophobic uncharged 0.205 2.0 ± 1.0 72.8 ± 4.5 –
Leu330Phe Hydrophobic uncharged 0.192 1.0 ± 0 – 88.9% ± 11.3%
Leu330Pro Uncharged – 4.0 ± 0 – –
Leu330Ser Hydrophilic uncharged 0.186 4.7 ± 0.6 – –
Leu330Thr Hydrophilic uncharged 0.193 4.3 ± 0.6 – –
Leu330Trp Hydrophobic uncharged – 4.0 ± 0 – 98.4% ± 7.3%
Leu330Tyr Hydrophobic ionizable 0.198 1.3 ± 0.6 150.6 ± 27.9 100.0%
Leu330Val Hydrophobic uncharged Hydrophobic uncharged 0.195 1.3 ± 0.6 164.9 ± 22.6 –
Gln331Ala Hydrophobic uncharged 0.205 1.0 ± 0 77.6 ± 8.0 –
Gln331Arg Hydrophilic basic 0.202 1.7 ± 0.6 – –
Gln331Asn Hydrophilic uncharged 0.203 2.0 ± 0 – 80.5% ± 17.1%
Gln331Asp Hydrophilic acidic 0.211 1.3 ± 0.6 – –
Gln331Cys Uncharged hydrophobic – 3.0 ± 0 – –
Gln331Glu Hydrophilic uncharged 0.203 2.0 ± 0 – –
Gln331Gly Hydrophilic acidic 0.203 1.7 ± 0.6 – –
Gln331His Uncharged 0.217 1.0 ± 0 153.0 –
Gln331Ile Hydrophilic basic 0.204 2.0 ± 0 – –
Gln331Leu Hydrophobic uncharged 0.209 2.0 ± 0 – –
Gln331Lys Hydrophilic basic 0.199 1.0 ± 0 – –
Gln331Met Hydrophobic uncharged 0.203 1.3 ± 0.6 – –
Gln331Phe Hydrophobic uncharged 0.186 2.0 ± 0 46.3 –
Gln331Pro Uncharged 0.197 3.3 ± 0.6 37.9 ± 13.2 –
Gln331Ser Hydrophilic uncharged 0.184 1.0 ± 0 – –
Gln331Thr Hydrophilic uncharged 0.194 2.0 ± 0 56.2 ± 6.8 –
Gln331Trp Hydrophobic uncharged 0.192 4.0 ± 0 107.7 ± 14.7 –
Gln331Tyr Hydrophobic ionizable – 2.7 ± 0.6 – –
Gln331Val Hydrophilic uncharged Hydrophobic uncharged – 2.3 ± 0.6 – –
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The majority of tolerated mutations (16/30) were found at
codon 331. Eight tolerated mutations were found at codon
330 and the remaining six tolerated mutations were at
codon 332.
Red/white colony plate p53 functional assay
Red/white colony screening, among the most commonly
applied p53 functional screens, was used to validate our
growth competition methodology and results. Mutant p53
expression plasmids were individually used to transform
the ARHGEF7 strain. Three colonies from each trans-
formation were grown on low adenine agar plates and
scored on a scale of 1 (whitest, active p53 mutants) to 5
(reddest, inactive p53 mutants) by three evaluators. The
average and standard deviation of the three scores is
reported in Table 1. Strains with a score less than 3.0
were assumed to express an active p53 mutant and those
with a score of 3.0 or greater were assumed to express
inactive p53.
Growth competition (GC) and Red/White assay (RW)
results agreed in 88% of the cases tested (50/57). The GC
correctly identified 93% (25/27) of the active p53 mutants
identified by the RW. Gln331Tyr and Gln331Val were
identified as active by the RW but missed by the GC. The
resulting false negative rate was approximately 4% (2/57).
17% of the mutants (5/30) that were identified as active
by the GC were identified as inactive by the RW (false
positives). However, in three of the five cases there is
ambiguous or contradictory data. Gln331Trp had a RW
score of 4.0 but expression profiling (see below) indicates
that this mutant has approximately WT activity, suggest-
ing that the GC rather than RW score is correct.
Gln331Pro had a borderline RW score (3.3) and protein
activity (37.9% WT) in the ambiguous range. Ile332Asn
also had a measured protein activity (33.1%) in the
ambiguous range. No additional data was available for the
two remaining false positives, Leu330Ser or Leu330Thr.
It is likely that the true number of false positives was
between 2 and 5, resulting in a false positive rate of
approximately 4–9%.
Gene expression assay for p53 activity
The ability of mutant p53 to activate transcription of the
ADE2 gene was assayed for 24 individual strains by
measuring transcript levels of p53 and ADE2 using pol-
onies. An approximate p53 protein activity level, reported
as %WT Activity in Table 1, was calculated for each
mutant tested based upon the ratio of ADE2:p53 tran-
scripts. In the 11 cases where p53 protein activity was
greater than 55% of WT the GC identified all 11 and the
Table 1 continued
Mutant WT AA Mutant AA Polony l (h–1) Red/White %WT activity p53 Western blot
Ile332 Ala Hydrophobic uncharged – 4.3 ± 0.6 14.7 –
Ile332Arg Hydrophilic basic – 5.0 ± 0 – –
Ile332Asn Hydrophilic uncharged 0.205 5.0 ± 0 33.1 –
Ile332Asp Hydrophilic acidic – 5.0 ± 0 – –
Ile332Cys Uncharged hydrophobic 0.202 1.0 ± 0 – 86.1% ± 6.9%
Ile332Gln Hydrophilic uncharged – 5.0 ± 0 – –
Ile332Glu Hydrophilic acidic – 5.0 ± 0 26.9 ± 6.9 122.2% ± 25.5%
Ile332Gly Uncharged – 4.0 ± 0 – –
Ile332His Hydrophilic basic – 5.0 ± 0 – 110.9% ± 12.0%
Ile332Leu Hydrophobic uncharged 0.198 1.0 ± 0 84.2 –
Ile332Lys Hydrophilic basic – 5.0 ± 0 – –
Ile332Met Hydrophobic uncharged 0.190 2.0 ± 0 179.2 ± 35.8 –
Ile332 Phe Hydrophobic uncharged – 5.0 ± 0 – –
Ile332Pro Uncharged – 5.0 ± 0 – –
Ile332Ser Hydrophilic uncharged – 4.7 ± 0.6 35.4 –
Ile332Thr Hydrophilic uncharged 0.192 2.3 ± 0.6 – 101.0% ± 6.6%
Ile332Trp Hydrophobic uncharged – 4.7 ± 0.6 – –
Ile332Tyr Hydrophobic ionizable – 4.7 ± 0.6 – –
Ile332Val Hydrophobic uncharged Hydrophobic uncharged 0.198 2.7 ± 0.6 56.0 –
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123
RW identified 10 (Gln331Trp was the exception) as active
p53 mutants. Similarly, when protein activity was less than
30% of WT both the GC and the RW identified all mutants
(7/7) as inactive. Six of the mutants tested had protein
activity levels in the range 30–55% WT activity. In this
range of activity, the GC and the RW generally agreed in
evaluating mutants. In four of six cases, GC and RW
concurred in scoring mutants either active or inactive; a
fifth mutant (Gln331Pro) was scored active by the GC but
had a borderline inactive RW score (3.3). However,
between 30 and 55% WT activity, GC and RW scores were
not well correlated with protein activities measured by the
gene expression assay. For example, Leu330Glu had the
highest protein activity score (54.4% WT) in the 30–55%
range but was scored inactive by the GC and the RW (score
of 5.0) whereas Gln331Phe had a lower measured protein
activity (46.3% WT) but was scored active by the GC and
the RW (score 2.0).
p53 protein expression analysis
Relative p53 protein expression levels of nine (arbitrarily
selected) mutants from our mutant library were determined
by Western blot (Table 1). p53 protein concentrations were
normalized with the value of the Leu330Tyr mutant which
was in the center of the range. Each mutant tested
expressed p53 at a similar level (80.5–122.2% of the
Leu330Tyr value) irrespective of protein activities mea-
sured by the GC, RW or the gene expression assay.
Discussion
The objective of this work was the development and
application of an assay to identify functional and non-
functional single amino acid changes in the human tumor
suppressor and transcription activator, p53, and to do so in
a highly parallel manner. There are currently several
technologies available capable of assaying the function of
p53. However, each is either inherently low throughput or
is incompatible with recently reported ultrahigh-throughput
DNA sequencing technologies (Margulies et al. 2005;
Shendure et al. 2005), the application of which will likely
revolutionize functional genomics. With these new tech-
nologies in mind, we designed a growth competition based
p53 functional assay which utilizes highly-parallel meth-
odology at every phase (i.e. mutant gene construction,
expression vector construction, mutant strain library
assemble and assay readout).
In this work, a library consisting of all possible single
amino acid substitutions at three positions (57 total)
within the tetramerization domain of the p53 protein was
screened for active and inactive mutants using our highly-
parallel growth competition based functional assay.
Although, most p53 mutations that are observed clinically
are located in the DNA-binding domain, the importance
of the tetramerization domain has been recognized and
several mutation affecting residues 330–331 have been
observed (reviewed in (Chene 2001)). Many reports have
characterized such mutant proteins. The amino acid
positions tested—Leu330, Gln331 and Ile332—are found
within a b-strand spanning residues 326–333 (Fig. 3)
which immediately precedes a 22 amino acid a-helix
(residues 335–356). Functional tetramer formation arises
from interactions between these subunit a-helices (Chene
and Bechter 1999). Tetramer formation and stability are
also dependant upon the interaction of Leu330 and Ile332
in the b-sheet with Phe341 in the a-helix. Side chains of
these three amino acids are in close proximity and form a
hydrophobic pocket necessary for protein activity (Rol-
lenhagen and Chene 1998).
Results of our functional screen were consistent with
this observation. Six of the eight tolerated mutations at
amino acid 330 were hydrophobic or uncharged (Leu330-
Cys) substitutions. The two hydrophilic substitutions that
were tolerated (Leu330Ser and Leu330Thr) were likely
false positives based upon their RW scores. Additionally, it
appears that the size of the hydrophobic R-group substi-
tution at position 330 had minimal impact on the function
of the protein; only the smallest and largest R-group sub-
stitutions, Leu330Ala and Leu330Trp, resulted in inactive
mutant proteins. Similar results were observed at Ile332.
Fig. 3 Human p53 tetramerization domain. Interacting regions of
two p53 monomers (peptide backbones visualized in green and blue)
which form a dimer. A second identical dimer (not shown) mates with
the first to form the final assembled protein. Side chains of the three
residues tested in this work, Leu330, Gln331 and Ile332, and the side
chain of Phe341 are highlighted. R-groups of Leu330, Ile332 and
Phe341 are oriented toward each other and form a portion of the
hydrophobic pocket, which stabilizes the p53 tetramer
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Four of the six tolerated mutations were hydrophobic or
uncharged (Ile332Cys). Based upon its RW score (5.0), it is
likely that Ile332Asn, one of the tolerated hydrophilic
substitutions, was a false positive. In Ile332, the size range
of tolerated mutations was smaller than that of Leu330.
Ile332Ala and each of the large ring structured amino acid
mutants (i.e. Ile332Phe, Ile332Tyr and Ile332Trp) were
inactive. A priori, it was not expected that mutations at
Gln331 would have a significant impact on protein activity.
Our functional screen confirmed this hypothesis; sixteen of
the nineteen possible amino acid substitutions at this
position were identified as functional. The three substitu-
tions at Gln331 identified as nonfunctional (Gln331Cys,
Gln331Tyr and Gln331Val) appear to be false negatives
based upon their RW scores.
We validated our growth competition methodology and
results in four separate ways. The first validation was the
inclusion of mutants of known activity in the screen. Three
of these mutants, Leu330His, Gln331Ala and Ile332Ala,
had previously reported activities relative to wild type p53
ranging from approximately 0–30% (Chene and Bechter
1999; Rollenhagen and Chene 1998); each was identified
by the GC as inactive. Gln331Ala, with a reported activity
approximately 80% that of wild type p53 (Chene and
Bechter 1999), was identified by the GC as active. The
second validation was the concurrent screening of all
mutant strains included in the GC using the standard Red/
White colony screen for p53 activity. There was approxi-
mately 90% agreement between the GC and the RW; the
majority of the conflicting results (5/7) were false positives,
i.e. mutants identified by the GC as active but scored
inactive by the RW. The rate of false negatives was
approximately 4% while the rate of false positives was
approximately 4–9%. Relative to the RW, the GC had a
sensitivity of 93% and specificity of 83%. p53 protein
expression measurements using Western blots were the
third validation of the GC methodology. Each of the nine
mutant p53 strains tested expressed the p53 monomer at a
similar level although their activities spanned the entire
range. mRNA transcription rates from the p415CYC1
expression vector have been previously demonstrated to
vary little from clone to clone (Merritt et al. 2003; Merritt
et al. 2005). Therefore, similar p53 monomer concentra-
tions among the mutants tested indicate similar rates of
protein translation and degradation. The fourth validation
of the GC methodology was a direct measurement of
transcriptional activation of the ADE2 reporter gene by p53
mutants using polonies. All mutants which had above 55%
wild type p53 activity, as measured by the ratio of ADE2/
p53 transcripts, were identified by the GC as active (the
RW assay agreed in 10/11 cases). Similarly, all mutants
which tested below 30% wild type activity were identified
as inactive (7/7, both GC and RW). Mutants whose activity
was measured in the intermediate range, 30–55% wild
type, had poor qualitative correlation between transcription
based activity measurements and functional assays. It can
therefore be concluded that our assay, as designed, is most
effective at identifying p53 mutants with activities less than
30% or greater than 55% wild type activity.
The primary limitations of the growth competition p53
assay as designed and presented in this work were the
inability to accurately measure mutant activities in the 30–
55% wild type activity range and the inability to quantita-
tively measure the growth rates of strains expressing low
activity p53 mutants. We hypothesize that both limitations
arise from suboptimal assay design, i.e. a non-linear response
in growth rate of the mutant bearing strain to changes in the
specific activity of the mutant p53 being expressed by the
strain. It may be possible to overcome these limitations by
optimizing several parameters. For example, it may be pos-
sible to discriminate lower activity mutants under conditions
of high p53 protein concentration or to discriminate high
activity mutants under limiting protein concentrations. To
this end, the assay could be redesigned to express p53 under
Fig. 4 Possible high throughput mutant construction and analysis.
Only minor modifications to the procedures for mutant construction
and analysis used in this work are required to greatly increase
throughput and compatibility with ultrahigh throughput sequencing
methods. (A) Random mutagenesis of portion of gene using
mutagenic crossover PCR, error prone PCR, annealing degenerate
single-stranded synthetic oligonucleotides, etc.; length of mutant
portion of gene limited by sequencing method employed. (B)
Construction of growth competition-ready mutant strain library using
gap repair cloning. (C) Pooled mutant growth competition. (D)
Mutant segment isolation and sequencing preparation using PCR. (E)
Chip-based ultrahigh throughput sequencing
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the control of a variable strength promoter such as CUP1
(Robinson et al. 1996) or GAL1 (Inga et al. 2002) or under
the control of an optimized fixed strength promoter. A sec-
ond parameter of the assay that might be optimized is the rate
of reporter molecule production which allows growth in the
presence of active p53. Several options are available to this
end. The most attractive would involve switching the
reporter from the ADE2 system to a HIS3 reporter. The
His3p enzyme is stoichiometrically inhibited by 3-amino-
1,2,4-triazole (AT) (Bitter et al. 2002). Therefore, varying
amounts of AT could be used to modulate His3p levels to
concentrations appropriate to discriminate different levels of
activity in p53 mutants. Alternatively, different p53 response
elements could be utilized in the reporter construct which
result in different levels of reporter transcription (Tomso
et al. 2005; Inga et al. 2002; Campomenosi et al. 2001;
Resnick and Inga 2003).
As alluded to earlier, our growth competition method-
ology was designed to utilize recently reported ultrahigh
throughput sequencing technologies. Our polony based
method presents a significant advantage in throughput
relative to standard screens such as the red/white colony
plate screen utilized in this work. However, the physical
size of polonies limits the number of data points per polony
slide to approximately 1000. As a result, the number of
different mutants that can be put into a single competition
and the concentration range of individual mutants in the
competition that can be accurately measured are limited.
Furthermore, the inability to directly sequence multinu-
cleotide runs of polony DNA requires that mutants (a) be
identified using the tagging method that we describe and
(b) limits the throughput of mutant expression vector
construction. The method reported by Margulies et al.
(2005) would allow an increase in the number of data
points per sequencing of approximately 102–103 fold and
direct sequencing of approximately 100 bp. Therefore it
would be possible to assess the impact of mutations at any
position in a typical gene in approximately 10 sequencing
runs. The method reported by Shendure et al. (2005) would
allow an increase of approximately 104–105 fold points per
run (with respect to polonies) but is somewhat more limited
in sequence read length (approximately 26 bp for this
application). With modest modifications to the system we
describe here and use of high throughput sequencing
technologies, whole gene mutation analysis could be
readily accomplished thus helping to elucidate the func-
tional consequences of SNPs (Fig. 4).
Appendix
Oligonucleotide primers used in this report. All primers were
supplied salt-free (Operon). [5Acrd] denotes a 5’ acrydite
modification. [phosp] denotes added phosphate group.
Name Mutation Sequence
279 Leu330 Ala TCGGAACATCTCGAAGCGCTCACGCCCACGGATCTGGGCGGTGAAATATTCTCCATCCA
273 Leu330 Arg TCGGAACATCTCGAAGCGCTCACGCCCACGGATCTGNNNGGTGAAATATTCTCCATCCA
273 Leu330 Asn See Above
280 Leu330 Asp TCGGAACATCTCGAAGCGCTCACGCCCACGGATCTGATCGGTGAAATATTCTCCATCCA
281 Leu330 Cys TCGGAACATCTCGAAGCGCTCACGCCCACGGATCTGGCAGGTGAAATATTCTCCATCCA
282 Leu330 Gln TCGGAACATCTCGAAGCGCTCACGCCCACGGATCTGCTGGGTGAAATATTCTCCATCCA
283 Leu330 Glu TCGGAACATCTCGAAGCGCTCACGCCCACGGATCTGCTCGGTGAAATATTCTCCATCCA
284 Leu330 Gly TCGGAACATCTCGAAGCGCTCACGCCCACGGATCTGGCCGGTGAAATATTCTCCATCCA
273 Leu330 His See Above
273 Leu330 Ile See Above
– Leu330 Leu –
285 Leu330 Lys TCGGAACATCTCGAAGCGCTCACGCCCACGGATCTGCTTGGTGAAATATTCTCCATCCA
286 Leu330 Met TCGGAACATCTCGAAGCGCTCACGCCCACGGATCTGCATGGTGAAATATTCTCCATCCA
287 Leu330 Phe TCGGAACATCTCGAAGCGCTCACGCCCACGGATCTGGAAGGTGAAATATTCTCCATCCA
273 Leu330 Pro See Above
273 Leu330 Ser See Above
273 Leu330 Thr See Above
288 Leu330 Trp TCGGAACATCTCGAAGCGCTCACGCCCACGGATCTGCCAGGTGAAATATTCTCCATCCA
289 Leu330 Tyr TCGGAACATCTCGAAGCGCTCACGCCCACGGATCTGATAGGTGAAATATTCTCCATCCA




273 Leu330 Val See Above
290 Gln331 Ala TCGGAACATCTCGAAGCGCTCACGCCCACGGATGGCAAGGGTGAAATATTCTCCATCCA
274 Gln331 Arg TCGGAACATCTCGAAGCGCTCACGCCCACGGATNNNAAGGGTGAAATATTCTCCATCCA
291 Gln331 Asn TCGGAACATCTCGAAGCGCTCACGCCCACGGATGTTAAGGGTGAAATATTCTCCATCCA
292 Gln331 Asp TCGGAACATCTCGAAGCGCTCACGCCCACGGATATCAAGGGTGAAATATTCTCCATCCA
293 Gln331 Cys TCGGAACATCTCGAAGCGCTCACGCCCACGGATGCAAAGGGTGAAATATTCTCCATCCA
– Gln331 Gln –
274 Gln331 Glu See above
294 Gln331 Gly TCGGAACATCTCGAAGCGCTCACGCCCACGGATGCCAAGGGTGAAATATTCTCCATCCA
295 Gln331 His TCGGAACATCTCGAAGCGCTCACGCCCACGGATGTGAAGGGTGAAATATTCTCCATCCA
274 Gln331 Ile See above
274 Gln331 Leu See above
296 Gln331 Lys TCGGAACATCTCGAAGCGCTCACGCCCACGGATCTTAAGGGTGAAATATTCTCCATCCA
297 Gln331 Met TCGGAACATCTCGAAGCGCTCACGCCCACGGATCATAAGGGTGAAATATTCTCCATCCA
298 Gln331 Phe TCGGAACATCTCGAAGCGCTCACGCCCACGGATGAAAAGGGTGAAATATTCTCCATCCA
274 Gln331 Pro See above
274 Gln331 Ser See above
274 Gln331 Thr See above
274 Gln331 Trp See above
299 Gln331 Tyr TCGGAACATCTCGAAGCGCTCACGCCCACGGATATAAAGGGTGAAATATTCTCCATCCA
274 Gln331 Val See above
Appendix
Name Sequence Purpose
272 AAACACAAATACACACACTAATCTAATGGAGGAGCCGCAGTCAGATCCTAGCGTC Common primer for p53, 50 end
271 TAAATTACTATACTTCTATAGACACGCAAACACAAATACACACACTAATCTAATG Mutant p53 ampli-fication and
addition of restriction sites278 CAGAGCTTGTGGGGGTTCACCCACTTGTAGGTGCCCTCATACTGGTCAGTC
276 CGTGGGCGTGAGCGCTTCGAGATGTTCCGA Primers for p53, 30 end
277 CACTTGTAGGTGCCCTCATACTGGTCAGTCTGAGTCAGGCCCTTCTGTCTTGAAC
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